20 results about "Bone marrow transplants" patented technology

This document provides methods and materials involved in treating myeloid neoplasms (e.g., myeloid cancers such as acute myeloid leukemia (AML)). For example, methods and materials for making and / or using T cells expressing (e.g., engineered to express) (a) one or more chimeric antigen receptors (CARs) having the ability to bind to a myeloid-specific polypeptide (e.g., a CD33 polypeptide) and (b) one or more inhibitory CARs (iCARs) having the ability to bind to a class I major histocompatibility complex (MHC) polypeptide (e.g., an HLA-A polypeptide such as an HLA-A2 polypeptide). In some cases, T cells provided herein can be administered to a mammal (e.g., a human) having a myeloid neoplasm (e.g., a myeloid cancer such as AML) and having received a haploidentical bone marrow transplant to target (e.g., target and destroy) the mammal's myeloid cells while sparing the donor-derived myeloid cells.

The disclosure relates generally to methods and compositions for performing bone marrow transplants using a non-myeloablative chemotherapeutic agent and chemotherapeutic-resistant cells. Using the methods and compositions described herein, a patient's bone marrow may be reconstituted and the patient avoids adverse side effects, including myeloablation and / or an impaired immune system.

The present invention provides a method and related equipment for early warning of myelosuppression risk caused by treatment, which are applied to the field of data processing technology. The present application processes the multimodal data information of a target user to generate a target physiological state prediction factor; processes the target user's serum marker characteristic information to generate a myelosuppression influencing factor; processes the target user's lifestyle information to generate a myelosuppression risk adjustment factor; processes the myelosuppression influencing factor and the myelosuppression risk adjustment factor to generate dynamic risk parameter information for the target user; and processes the target physiological state prediction factor and the target user's dynamic risk parameter information based on a target high-dose methotrexate myelosuppression risk prediction model to generate a myelosuppression risk value and a bone marrow transplant risk level.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with or inhibit the expression of the TMPRSS6 gene in combination with one or more iron chelators and possibly other active agents, as well as to therapeutic uses such as the treatment of hemochromatosis, porphyria, and blood disorders such as beta-thalassemia, sickle cell anemia, and transfusion iron overload or myelodysplastic syndrome, as well as infections and mortality not related to relapses associated with bone marrow transplantation.

The present invention relates to a composition comprising C-C motif chemokine ligand 5 (CCL5) for promoting the activation of bone marrow-derived stem cells. It is identified that, when CCL5, which is a niche-enhancing factor, is injected together with growth related oncogene beta (GROβ), which is known to promote the mobilization of hematopoietic stem cells from the bone marrow into peripheral blood, and AMD3100, which is a CXCR4 antagonist, the migration of hematopoietic stem cells from bone marrow to peripheral blood increases, and the engraftment rate also increases when the hematopoietic stem cells are injected into recipients undergoing bone marrow transplantation. Therefore, the CCL5 protein, GROβ, and the CXCR4 antagonist AMD3100 are provided as a composition for promoting the activation of bone marrow-derived stem cells, and thus bone marrow-derived stem cells activated thereby is provided as a novel therapeutic means for bone marrow diseases requiring bone marrow transplantation.

The present application relates to a kind of acute leukemia (ALL) high flux flow detection kit, belong to leukemia detection field, the present application is based on the original 8 color flow to increase 16 kinds of ALL cell antigen, can realize the simultaneous detection of 24 kinds of antigens in the same cell, not only greatly improve the detection precision of micro residual lesion (MRD), and by being divided into 12 development stages to ALL cell, can more accurately identify immunotyping when first diagnosis, and immunophenotypic aberration after bone marrow transplantation and after CAR-T cell therapy, this has very important guiding significance to the evaluation of patient treatment effect and the adjustment of treatment scheme.

The invention discloses a reagent and / or a kit for identifying or assisting in identifying whether a bone marrow transplantation patient is infected with aspergillus fumigatus or not and application of the reagent and / or the kit, and belongs to the field of microbiological detection. The technical problem to be solved by the invention is how to quickly and accurately detect and / or identify aspergillus fumigatus. For example, how to detect and / or identify whether a sample to be determined contains aspergillus fumigatus or not through a visualization method and how to distinguish the content of fungi in the sample through the visualization method. Therefore, the invention provides a kit for screening whether a bone marrow transplantation patient is infected with aspergillus fumigatus, the kit comprises a primer pair for specifically amplifying a specific recognition fragment of aspergillus fumigatus, and the specific recognition fragment of aspergillus fumigatus is a DNA molecule of which the nucleotide sequence is a sequence 1 in a sequence table. According to the technical scheme provided by the invention, the detection sensitivity of the aspergillus fumigatus is high, and the aspergillus fumigatus with fg-level gene concentration can be accurately identified; the detection specificity is good, and the aspergillus fumigatus can be specifically detected in various pathogenic bacteria samples.

Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.

Disclosed are methods for evaluating genetic models that are predictive of autoimmune disease phenotype or status. The methods comprise obtaining genotype data from bone marrow transplant recipients and donors. The autoimmune disease phenotype of the transplant recipient after the transplantation may be used evaluate the effect of genotype on the autoimmune disease. Phenotype comparisons may be made to the transplant donor and / or the transplant recipient prior to the transplantation. The methods may be used to validate genetic models associated with autoimmune disease. The genetic models may be based on one or more genetic variants associated with susceptibility to or protection from an autoimmune disease.

The present invention provides a method and composition for performing bone marrow transplantation. [Solution] This disclosure relates, as a whole, to methods and compositions for performing bone marrow transplantation using non-myeloablative chemotherapeutic agents and chemotherapeutic-resistant cells. Using the methods and compositions described herein, a patient's bone marrow can be reconstituted, and the patient can avoid adverse side effects, including myeloablative and / or immune system disorders.

Embodiments are directed to a method of treating acute radiation syndrome comprising administering to a subject following exposure to radiation a PIF peptide. Some embodiments describe a method of treating acute radiation syndrome following radiation exposure comprising transplanting bone marrow that has been exposed to a PIF peptide prior to transplantation into a subject. Other embodiments describe a method of increasing engraftment of a transplanted organ, tissue, or cell by pre-exposing the organ, tissue, or cell to a PIF peptide.

Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purifying and using rIVIG proteins. The compositions comprise oligomeric Fc molecules that bind Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules to treat immune disorders, including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves' disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins are also useful as immunomodulatory agents for patients to reduce immune rejection of organ transplants, stem cell transplants, and bone marrow transplants. In addition, the present invention provides rIVIG proteins of non-human origin for use in veterinary immune disorders, such as canine rIVIG proteins for treating dogs with autoimmune hemolytic anemia, immune thrombocytopenic purpura, rheumatoid arthritis, or other canine immune disorders.

This utility model discloses a bone marrow transplant ward, which includes a clean room, an external transparent window, an external guide structure, and an external sliding door. The clean room has an external observation opening and an external passage opening on its side wall, located on the same side wall. The external transparent window is located at the external observation opening. The external guide structure is located in the clean room and extends from the external passage opening to the external observation opening. The external sliding door is slidably mounted on the external guide structure, with its sliding direction matching the extension direction of the external guide structure. During sliding, the external passage opening can be opened and closed, and when the external passage opening is opened, it slides at least partially to the external observation opening. In this design, the external transparent window is at least partially located within the sliding stroke of the external sliding door, reducing additional space occupation and facilitating application in situations where ward space is limited. Furthermore, the external transparent window expands the field of vision for people outside, facilitating visits to patients inside and improving convenience. The structure is also simple and cost-effective.

The invention relates to CD34+ hematopoietic stem cells modified via enrichment with mitochondria isolated from mesenchymal stem cells (MSCs) in an oxidative phosphorylation (OXPHOS) metabolic state. Mesenchymal cells are preferably obtained from the umbilical cord. The CD34+ cells modified in this way exhibit improved functional properties, including increased viability, resistance to oxidative stress, and enhanced hematopoietic transplantation capacity. The invention also relates to a method for mitochondrial transfer to CD34+ cells, as well as pharmaceutical compositions comprising said cells for use in hematological and autoimmune therapies, specifically in bone marrow transplants.

The invention relates to medicine, and more particularly to methods for matching a donor bone marrow transplant to a recipient, and can be used for determining the compatibility of genetic substances of transplants. The problem addressed is that of identifying a suitable donor. According to the invention, values of ten gene loci А, В, С, DRB1, DQB1 on recipient and donor chromosomes are obtained using HLA typing technology and said values are statistically processed to find the best compatibility between donor and recipient bone marrow. The technical result is that of achieving the intended purpose by means of the invention.

The disclosure relates generally to methods and compositions for performing bone marrow transplants using a non-myeloablative chemotherapeutic agent and chemotherapeutic-resistant cells. Using the methods and compositions described herein, a patient's bone marrow may be reconstituted and the patient avoids adverse side effects, including myeloablation and / or an impaired immune system.

The present disclosure provides cells and hematopoietic organoid compositions, and methods of making and using the same for bone marrow transplants, cell therapy and treatment of diseases or disorders associated with hematopoietic cell disfunction or deficiency and / or immune cell disfunction or deficiency.

Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose. The actinium-225 labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or a radiosensitizing agent, or additional therapeutic interventions, such as bone marrow transplant or adoptive cell therapies.

Provided herein are methods for preparing a subject for a conditioning treatment and / or reducing the toxicity of a conditioning treatment in a subject, wherein the subject is in need of a hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT). Also provided are methods for increasing the recovery of a subject administered a HSCT or BMT. The subject in need of the HSCT or the BMT can, for example, be suffering from a disease or condition associated with increased inflammation prior to the HSCT or BMT.